Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZAI LAB

21.600
-7.200-25.00%
Volume:18.00M
Turnover:416.47M
Market Cap:23.78B
PE:-10.70
High:24.600
Open:24.500
Low:21.400
Close:28.800
Loading ...

BUZZ-HK-listed Zai Lab hits 2-year peak on higher product revenue

Reuters
·
28 Mar

Stock Track | Zai Lab Soars 5.23% as Annual Revenue Jumps Despite Net Loss

Stock Track
·
28 Mar

BRIEF-Zai Lab Posts FY Net Loss $257.1 Million

Reuters
·
28 Mar

Zai Lab - FY Net Product Revenue Increased to $397.6 Mln

THOMSON REUTERS
·
28 Mar

Zai Lab's Q4 2024 Net Loss Narrows; Revenue Beats Estimates

MT Newswires Live
·
28 Feb

Stock Track | Zai Lab Plummets 5.21% on Disappointing Q4 Earnings, Wider Loss

Stock Track
·
28 Feb

Zai Lab Ltd : Leerink Partners Raises Target Price to $74 From $72

THOMSON REUTERS
·
28 Feb

Zai Lab Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Zai Lab Ltd Outlook FY 2025 Total Revenue $560 Mln to $590 Mln

THOMSON REUTERS
·
27 Feb

Zai Lab Ltd - Q4 Total Revenues $109.1 Million

THOMSON REUTERS
·
27 Feb

Zai Lab Ltd expected to post a loss of 65 cents a share - Earnings Preview

Reuters
·
25 Feb

Zai Lab Receives Orphan Drug Designation From the U.S. FDA for Zl-1310 (Dll3 ADC) for the Treatment of Small Cell Lung Cancer (Sclc)

THOMSON REUTERS
·
23 Jan

BRIEF-Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Reuters
·
17 Jan

Zai Lab Announces Acceptance of New Drug Application for Karxt for the Treatment of Schizophrenia

THOMSON REUTERS
·
17 Jan

BRIEF-Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Reuters
·
15 Jan

Zai Lab Ltd: Safety Profile of Tivdak Among China Subpopulation Was Manageable and Consistent With That Observed in Global Populatio

THOMSON REUTERS
·
15 Jan

Zai Lab Announces Positive Topline Results for Tivdak in the China Subpopulation of the Global Phase 3 Innovatv 301 Trial in Patients With Recurrent or Metastatic Cervical Cancer

THOMSON REUTERS
·
15 Jan

Zai Lab Ltd - to Submit Nda for Tivdak to Nmpa in Q1 2025

THOMSON REUTERS
·
15 Jan

Zai Lab Ltd - Median Os for Tivdak Not Reached VS Chemotherapy 10.7 Months

THOMSON REUTERS
·
15 Jan

BRIEF-Zai Lab, Vertex Sign Strategic Agreement To Develop, Commercialize Povetacicept In Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region And Singapore

Reuters
·
10 Jan